CRP and rheumatoid arthritis: Another interesting approach is the antisense oligonucleotide ISIS-CRPRx, which reduces the CRP production in the liver and is currently tested in a phase 2 study on patients with rheumatoid arthritis, according to the manufacturer's website with promising success.